DK1007092T3 - En fremgangsmåde til inhibering af komplementaktivering via det alternative forlöb - Google Patents

En fremgangsmåde til inhibering af komplementaktivering via det alternative forlöb

Info

Publication number
DK1007092T3
DK1007092T3 DK98944501T DK98944501T DK1007092T3 DK 1007092 T3 DK1007092 T3 DK 1007092T3 DK 98944501 T DK98944501 T DK 98944501T DK 98944501 T DK98944501 T DK 98944501T DK 1007092 T3 DK1007092 T3 DK 1007092T3
Authority
DK
Denmark
Prior art keywords
alternative pathway
complement activation
activation via
inhibiting complement
inhibiting
Prior art date
Application number
DK98944501T
Other languages
Danish (da)
English (en)
Inventor
Kurt R Brunden
Rekha Gupta-Bansal
James B Parent
Original Assignee
Amgen Fremont Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Fremont Inc filed Critical Amgen Fremont Inc
Application granted granted Critical
Publication of DK1007092T3 publication Critical patent/DK1007092T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Pyrane Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • External Artificial Organs (AREA)
  • Fats And Perfumes (AREA)
  • Cereal-Derived Products (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
DK98944501T 1997-08-26 1998-08-24 En fremgangsmåde til inhibering af komplementaktivering via det alternative forlöb DK1007092T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US91834997A 1997-08-26 1997-08-26

Publications (1)

Publication Number Publication Date
DK1007092T3 true DK1007092T3 (da) 2006-10-02

Family

ID=25440234

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98944501T DK1007092T3 (da) 1997-08-26 1998-08-24 En fremgangsmåde til inhibering af komplementaktivering via det alternative forlöb

Country Status (13)

Country Link
US (3) US6333034B1 (fr)
EP (1) EP1007092B1 (fr)
JP (1) JP2001513576A (fr)
AT (1) ATE335511T1 (fr)
AU (1) AU756490B2 (fr)
CA (1) CA2302317A1 (fr)
DE (1) DE69835524T2 (fr)
DK (1) DK1007092T3 (fr)
ES (1) ES2270530T3 (fr)
NO (1) NO20000935L (fr)
NZ (1) NZ503033A (fr)
PT (1) PT1007092E (fr)
WO (1) WO1999010009A1 (fr)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6641571B2 (en) * 2000-01-05 2003-11-04 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Reduction of postoperative complications of cardiopulmonary bypass (CPB) surgery
EP2113516B1 (fr) 2000-10-10 2014-05-21 Genentech, Inc. Anticorps contre C5 inhibant l'activation de type II des cellules endothéliales
JP2004536138A (ja) * 2001-07-26 2004-12-02 アレクシオン ファーマシューティカルズ， インコーポレイテッド 認識機能を改善する方法
ES2198216B1 (es) * 2002-07-02 2005-04-16 Juan Carlos Instituto Cientifico Y Tecnologico De Navarra, S.A.(67%). Medio de cultivo de celulas madre-progenitoras autologas humanas y sus aplicaciones.
JP2006507841A (ja) * 2002-11-14 2006-03-09 ダーマコン， インコーポレイテッド 機能的ｓｉＲＮＡおよび超機能的ｓｉＲＮＡ
US7361339B2 (en) * 2003-01-09 2008-04-22 Alexion Pharmaceuticals, Inc. Methods for reducing morality associated with acute myocardial infarction
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
US20070123466A1 (en) * 2003-05-13 2007-05-31 New York Society For The Ruptured And Crippled Maintaining The Hospital For Special Surgery Method of treating recurrent miscarriages
US7959919B2 (en) * 2003-11-19 2011-06-14 Novelmed Therapeutics, Inc. Method of inhibiting factor B-mediated complement activation
DK1713503T3 (da) * 2004-02-10 2013-11-04 Univ Colorado Regents Hæmning af faktor b, den alternative komplemenpathway og dertil relaterede fremgangsmåde
DK1737487T3 (en) * 2004-03-30 2016-08-22 Canadian Blood Services Process for the treatment of autoimmune diseases with antibodies
BRPI0401765C1 (pt) * 2004-05-17 2011-03-15 Hy Biotecnologica Ltda método de enriquecimento de espermatozoides de mamìferos portadores de cromossomo x ou de cromossomo y
US7423128B2 (en) * 2004-11-03 2008-09-09 Amgen Fremont Inc. Anti-properdin antibodies, and methods for making and using same
US8911733B2 (en) * 2005-05-26 2014-12-16 Musc Foundation For Research Development Inhibition of the alternative complement pathway for treatment of traumatic brain injury, spinal cord injury and related conditions
PT2500030E (pt) * 2005-11-04 2015-09-24 Genentech Inc Uso de inibidores da via do complemento para tratar doenças oculares
BRPI0619249A2 (pt) 2005-11-30 2011-09-20 Abbott Lab anticorpos anti-globulÈmeros-aß, frações que se ligam a antìgeno destes, hibridomas correspondentes, ácidos nucléicos, vetores, células hospedeiras, métodos de produzir os ditos anticorpos, composições compreendendo os ditos anticorpos, usos dos ditos anticorpos e métodos de usar os ditos anticorpos
PT1976877E (pt) 2005-11-30 2014-04-29 Abbvie Inc Anticorpos monoclonais contra proteína beta-amilóide e suas utilizações
SI3028716T1 (sl) 2006-10-10 2021-01-29 Regenesance B.V. Komplementarna inhibicija za izboljšano regeneracijo živcev
PL2907827T3 (pl) * 2006-11-02 2019-03-29 Genentech, Inc. Humanizowane przeciwciała przeciw czynnikowi D i ich zastosowanie
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
EP2124952A2 (fr) 2007-02-27 2009-12-02 Abbott GmbH & Co. KG Méthode de traitement d'amyloïdoses
CA2680344A1 (fr) 2007-03-14 2008-11-20 Woodruff Emlen Anticorps anti-facteur b humanise
US9745367B2 (en) * 2007-03-23 2017-08-29 Novelmed Theraputics, Inc. Alternative pathway specific antibodies for treating arthritis
WO2008154018A2 (fr) * 2007-06-11 2008-12-18 The Trustees Of The University Of Pennsylvania Modulation de properdine de voie alternative et ses utilisations
US8981060B2 (en) 2007-08-27 2015-03-17 Novelmed Therapuetics, Inc. Method of inhibiting complement activation with factor Bb specific antibodies
US10131706B2 (en) 2007-08-27 2018-11-20 Novelmed Therapeutics, Inc. Anti-factor Bb antibodies
EP2262831B1 (fr) * 2008-03-03 2015-01-21 NovelMed Therapeutics, Inc. Anticorps anti-properdine
US20140127204A1 (en) 2010-09-03 2014-05-08 Novelmed Therapeutics, Inc. Anti-properdin antibodies
US8664362B2 (en) 2008-03-03 2014-03-04 NovelMed Therapeutics Humanized and chimeric anti-properdin antibodies
CR20170001A (es) 2008-04-28 2017-08-10 Genentech Inc Anticuerpos anti factor d humanizados
US20110160636A1 (en) * 2008-09-10 2011-06-30 Rekha Bansal Device and method for inhibiting complement activation
WO2010057084A1 (fr) * 2008-11-14 2010-05-20 Novelmed Therapeutics, Inc. Procédé de traitement d’une lésion de reperfusion ischémique
RS20120461A1 (sr) 2009-07-02 2013-06-28 Musc Foundation For Research Development Metode za stimulaciju regeneracije jetre
CN103068396B (zh) * 2010-03-02 2016-07-06 诺沃姆德治疗公司 抑制c5和备解素相互作用的抗-备解素抗体在制备抑制交替途径活化的药剂中的用途
CN103003302B (zh) * 2010-03-10 2015-09-30 诺沃姆德治疗公司 人源化和嵌合抗-备解素抗体
EP2558494B1 (fr) 2010-04-15 2018-05-23 AbbVie Inc. Protéines de liaison à la bêta amyloïde
CN105348387B (zh) 2010-08-14 2020-08-25 Abbvie 公司 β淀粉样蛋白结合蛋白
EP2723361B1 (fr) 2011-06-22 2019-10-30 Apellis Pharmaceuticals, Inc. Méthodes de traitement de troubles chroniques au moyen d'inhibiteurs de complément
WO2013006449A2 (fr) 2011-07-01 2013-01-10 The Trustees Of The University Of Pennsylvania Anticorps anti-properdine et leurs utilisations
ES2728278T3 (es) 2011-12-21 2019-10-23 Novartis Ag Composiciones que comprenden anticuerpos dirigidos al factor P y C5
CN104220453B (zh) * 2012-04-03 2018-03-09 诺沃姆德治疗公司 人源化的嵌合抗因子c3抗体及其用途
US9803005B2 (en) 2012-05-24 2017-10-31 Alexion Pharmaceuticals, Inc. Humaneered anti-factor B antibody
CN104870474B (zh) 2012-10-04 2019-03-12 诺沃姆德治疗公司 用于治疗溶血性疾病的旁路途径特异性抗体
ES2514165B1 (es) * 2013-03-27 2015-09-09 Consejo Superior De Investigaciones Científicas (Csic) Anticuerpo anti-factor b, composición farmacéutica útil para el tratamiento de enfermedades del complemento y sus aplicaciones
CR20160132A (es) 2013-08-12 2016-08-25 Genentech Inc Composiciones y método para tratar condiciones asociadas con el complemento
KR20160147855A (ko) 2014-05-01 2016-12-23 제넨테크, 인크. 항-인자 d 항체 변이체 및 이의 용도
HK1257422A1 (zh) 2015-10-30 2019-10-18 豪夫迈‧罗氏有限公司 抗-因子d抗体变体缀合物及其用途
EP3368074A2 (fr) 2015-10-30 2018-09-05 Hoffmann-La Roche AG Anticorps et conjugués anti-facteur d
EP3405577B8 (fr) 2016-01-20 2023-02-15 396419 B.C. Ltd. Compositions et procédés pour inhiber le facteur d
EP3275897A1 (fr) 2016-07-27 2018-01-31 Biotest AG Procédé de préparation de compositions d'immunoglobuline
EP3526248A4 (fr) 2016-10-17 2020-07-08 Musc Foundation for Research Development Compositions et méthodes de traitement d'une lésion du système nerveux central
WO2018136827A1 (fr) 2017-01-20 2018-07-26 Vitrisa Therapeutics, Inc. Compositions à boucle en épingle à cheveux et procédés pour inhiber le facteur d
GB2583560A (en) 2018-12-11 2020-11-04 Admirx Inc Fusion protein constructs for complement associated disease
US11981727B2 (en) 2021-08-31 2024-05-14 Novelmed Therapeutics, Inc Monospecific and bispecific antibodies and antigen binding fragments thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4642284A (en) * 1983-06-13 1987-02-10 Scripps Clinic And Research Foundation Method and system for detection of complement pathway activation
US5434075A (en) * 1992-03-20 1995-07-18 Board Of Trustees Of The University Of Illinois Monoclonal antibody to a human MDR1 multidrug resistance gene product, and uses
EP0751787B1 (fr) * 1994-03-23 2005-01-12 Alexion Pharmaceuticals, Inc. Procede permettant de reduire les dysfonctionnements des systemes immunitaire et hemostatique pendant la circulation extra-corporelle

Also Published As

Publication number Publication date
NO20000935D0 (no) 2000-02-25
PT1007092E (pt) 2006-12-29
DE69835524T2 (de) 2007-04-05
NZ503033A (en) 2003-01-31
WO1999010009A1 (fr) 1999-03-04
ES2270530T3 (es) 2007-04-01
JP2001513576A (ja) 2001-09-04
AU9203398A (en) 1999-03-16
US20030198636A1 (en) 2003-10-23
DE69835524D1 (de) 2006-09-21
AU756490B2 (en) 2003-01-16
US6333034B1 (en) 2001-12-25
NO20000935L (no) 2000-04-18
EP1007092B1 (fr) 2006-08-09
EP1007092A1 (fr) 2000-06-14
ATE335511T1 (de) 2006-09-15
US20020015701A1 (en) 2002-02-07
CA2302317A1 (fr) 1999-03-04

Similar Documents

Publication Publication Date Title
NO20000935L (no) Fremgangsmåte for inhibering av komplementaktivering via den alternative reaksjonsvei
DK0828717T3 (da) Fremgangsmåde til fremstilling af 3-haloalkyl-1H-pyrazol
IS5447A (is) Ferli til að smíða 1,3-díól
BG102474A (en) (-)-cis-6(s)-phenyl-5(r)-[4-(2-pyrrolidine-1-yletoxi)phenyl)-5,6,7 ,8-tetrahydronaphthalen-2-ol-d-tartarate
DK0960109T3 (da) Fremgangsmåde til fremstilling af tolterodin
DK0715631T3 (da) Fremgangsmåde til fremstilling af N-amino-1-hydroxyalkyliden-1,1-diphosphonsyrer
IS4147A (is) Aðferð til framleiðslu á 1,5 Benzodiazepine afleiðum
DK0787115T3 (da) Fremgangsmåde til fremstilling af 4a,5,9,10,11,12-hexahydro-6H-benzofuro[3a,3,2-ef][2]benzazepinderivater
DK0937055T3 (da) Fremgangsmåde til fremstilling af d,I-alfa-tocopherol
NO981688L (no) Chirale metylfenyloksazolidinoner
TR199601005A2 (tr) Uzun zincirli, dallanmis poliolefinlerin üretimi icin yöntem.
DK0885191T3 (da) Opspaltning af threo-methylphenidat
SE9804002D0 (sv) New manufacturing process
IS4190A (is) Hliðstæð aðferð til framleiðslu á 1,5 bensódíasepín afleiðum
MX9603277A (es) Metodo para moldear una camara de seccion decreciente.
ES2109103T3 (es) Procedimiento para la preparacion de trialquilsilil-7 bacatina iii.
ATE237568T1 (de) Neue substanzbibliothek und damit hergestellte supramolekulare komplexe
AU1160700A (en) Ppar gamma ligands
DK0931161T3 (da) Fremgangsmåde til biotransformation af colchicinoid-forbindelser til de tilsvarende 3-glycosylderivater
DK0815092T3 (da) Fremgangsmåde til fremstilling af 1,2-benzisothiazolin-3-oner
DK1206452T3 (da) Fremgangsmåde til fremstilling af benzoperhydro-isoindolforbindelser
DK0735043T3 (da) Fremgangsmåde til fremstilling af 2-substitueret 3,3-difluorfuran
BG103650A (en) Method for the preparation of eprosartan
NO20006205D0 (no) Morfin-6-glukuronidsyntese
DK0975569T3 (da) Fremgangsmåde til hydroxylering af 1,4-dichlorbenzen